The Recall Desk
ModerateFDA (Drugs)·D-0880-2017·Announced 2017-06-07

Saphris Asenapine Tablets Recalled for Labeling Mixup

Forest Laboratories is recalling Saphris (asenapine) sublingual tablets because blister packs labeled as 10 mg actually contain 5 mg tablets.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II and involves a labeling error (dose mixup) without reported injuries or illnesses, fitting the criteria for moderate severity.

Plain-English summary

Forest Laboratories, LLC is recalling 40,621 blister packs of Saphris (asenapine maleate) sublingual tablets. The recall involves lots W00733 and W00946 with an expiration date of April 2019. The product is distributed nationwide.

The recall was initiated due to a labeling mixup. The blister lidding foil and shell-pack are labeled as 10 mg, but the packages actually contain 5 mg tablets. This discrepancy could lead to patients receiving an incorrect dosage of the medication.

Consumers who have this product should stop using it and contact their healthcare provider or pharmacist for guidance. The product is a prescription-only medication manufactured by Catalent UK Swindon, Zydis Ltd, and distributed by Forest Pharmaceuticals, Inc.

The recalled product

Product
SAPHRIS (ASENAPINE MALEATE)
Brand
SAPHRIS
Affected units
40,621

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lots W00733 and W00946
  • exp Apr 2019

Distribution

Distributed nationwide across the United States.